Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05101551 | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy(PARPAML) | recruiting | Phase 1 | 34 | Norman J. LacayoOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07320235 | Imetelstat Combinations in Relapsed AML(IMAGINE) | recruiting | Phase 1 | 36 | Douglas TremblayOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | active not recruiting | Phase 1 | 17 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02390635 | PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04797767 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | recruiting | Phase 1 / Phase 2 | 62 | University of WashingtonOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06034002 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 290 | Incyte CorporationINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04140487 | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | recruiting | Phase 1 / Phase 2 | 97 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS(UHKT-PTC-TMI-1) | recruiting | Phase 1 / Phase 2 | 16 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03132454 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | active not recruiting | Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | recruiting | Phase 1 / Phase 2 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06561152 | Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML | recruiting | Phase 1 / Phase 2 | 20 | Stanford UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529951 | Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers | not yet recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 0 | Apr 14, 2026 | clinicaltrials |
| NCT05732103 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | recruiting | Phase 1 / Phase 2 | 225 | Chordia Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | recruiting | Phase 1 | 50 | University of Alabama at BirminghamOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06146257 | A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 48 | GluBio Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06419634 | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 105 | Bristol-Myers SquibbINDUSTRY | 4 | Apr 8, 2026 | clinicaltrials |
| NCT05263271 | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 58 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511062 | Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | not yet recruiting | Phase 1 | 32 | Northside Hospital, Inc.OTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02204085 | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 33 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03431090 | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia | active not recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms(LIMBER) | active not recruiting | Phase 1 | 140 | Incyte CorporationINDUSTRY | 8 | Apr 1, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT04716452 | Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia(KNAN2001) | recruiting | Phase 1 | 15 | Keystone Nano, IncINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | suspended | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04980404 | Inqovi Maintenance Therapy in Myeloid Neoplasms | active not recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05933070 | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML(LAUREL) | terminated | Phase 1 | 2 | Inmune Bio, Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | terminated | Phase 1 / Phase 2 | 13 | Servier Bio-Innovation LLCINDUSTRY | 6 | Mar 30, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | recruiting | Phase 1 | 38 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | recruiting | Phase 1 | 22 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07107126 | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 24 | Remedy Plan, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT04990102 | Phase IB/II of CPX-351 for Relapse Prevention in AML | recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04278768 | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 366 | Curis, Inc.INDUSTRY | 8 | Mar 19, 2026 | clinicaltrials |
| NCT06440135 | Ziftomenib Maintenance Post Allo-HCT | recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | terminated | Phase 1 / Phase 2 | 63 | Nerviano Medical SciencesINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05275439 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | terminated | Phase 1 | 106 | Shattuck Labs, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT05636514 | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS(CELESTIAL-MDS) | recruiting | Phase 1 | 12 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04347616 | Natural Killer-cell Therapy for Acute Myeloid Leukemia(NK4AML) | terminated | Phase 1 / Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06994676 | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias(CROSSCHECK-001) | recruiting | Phase 1 | 72 | Crossbow Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | recruiting | Phase 1 | 420 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). | recruiting | Phase 1 / Phase 2 | 33 | Gyala TherapeuticsINDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03232268 | HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies(MICROSTEM) | completed | Phase 1 | 25 | Institut Paoli-CalmettesOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2026source: clinicaltrials